Vaccine composition containing synthetic adjuvant
Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
1. A vaccine composition comprising:
(a) an antigen;
(b) a pharmaceutically acceptable carrier or excipient, and
(c) a lipid adjuvant of the formula:
wherein:
R 1 , R 3 , R 5 and R 6 are undecyl; and
R 2 and R 4 are tridecyl;
or a pharmaceutically acceptable salt thereof.
2. The composition of claim 1 wherein the adjuvant is synthetic.
3. The composition of claim 1 wherein the adjuvant is at least 80% pure, based on the total weight of lipid adjuvants in the composition.
4. The composition of claim 1 wherein the adjuvant is at least 95% pure, based on the total weight of lipid adjuvants in the composition.
5. The composition of claim 1 which has been sterile filtered.
6. The composition of claim 1 comprising a plurality of antigens.
7. The composition of claim 1 , further comprising at least one additional component selected from the group consisting of:
a toll-like receptor (TLR) agonist;
a saponin or saponin mimetic;
a co-adjuvant; and
a carrier that comprises at least one of an oil and an immunostimulatory complex.
8. The composition of claim 7 wherein:
(i) the TLR agonist, when present, is selected from the group consisting of lipopolysaccharide, peptidoglycan, polyl:C, CpG, 3M003, flagellin, Leishmania homolog of eukaryotic ribosomal elongation and initiation factor 4a (LeIF) and an imidazoquinoline immune response modifier; and
(ii) the co-adjuvant, when present, is selected from the group consisting of alum, a cytokine, a detergent, a block copolymer and a biodegradable polymer.
9. The composition of claim 1 wherein the antigen comprises at least one polypeptide antigen or at least one recombinant expression construct which comprises a promoter operably linked to a nucleic acid sequence encoding at least one polypeptide antigen.
10. A kit, comprising:
(a) an adjuvant composition in a first container, the adjuvant composition comprising a pharmaceutically acceptable carrier or excipient, and a compound of the formula:
wherein:
R 1 , R 3 , R 5 and R 6 are undecyl; and
R 2 and R 4 are tridecyl;
or a pharmaceutically acceptable salt thereof; and
(b) an antigen in a second container, wherein the adjuvant composition is not in contact with the antigen.
11. The kit of claim 10 wherein the adjuvant is synthetic.
12. The kit of claim 10 wherein the adjuvant is at least 80% pure, based on the total weight of lipid adjuvants in the composition.
13. The kit of claim 10 wherein the composition has been sterile filtered.
14. The kit of claim 10 wherein the containers are sterile.
15. The composition of claim 1 which is in the form of an oil-in-water emulsion.
16. The composition of claim 1 which is in the form of a water-in-oil emulsion.
17. The composition of claim 1 which is in the form of a microparticle.
18. The kit of claim 10 wherein the adjuvant composition is in the form of an oil-in-water emulsion.
19. The kit of claim 10 wherein the adjuvant composition is in the form of a water-in-oil emulsion.
20. The kit of claim 10 wherein the adjuvant composition is in the form of a microparticle.